Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota.
Department of Nephrology, University of Minnesota, Minneapolis.
JAMA Netw Open. 2023 Feb 1;6(2):e230806. doi: 10.1001/jamanetworkopen.2023.0806.
The Centers for Medicare & Medicaid Services designed a mandatory payment model to incentivize home dialysis use: the End-Stage Renal Disease Treatment Choices (ETC). Outpatient dialysis facilities and health care professionals providing nephrology services were randomly assigned to ETC participation at the hospital referral region level.
To assess the association between ETC and home dialysis use in the incident dialysis population in its first 18 months of implementation.
DESIGN, SETTING, AND PARTICIPANTS: A cohort study with controlled, interrupted time series analysis of the US End-Stage Renal Disease Quality Reporting System database was conducted, using generalized estimating equations. All adults initiating home-based dialysis in the US between January 1, 2016, and June 30, 2022, without a prior kidney transplant were included in the analysis.
Prior to vs after ETC onset in January 1, 2021, and random assignment to ETC participation of facilities and health care professionals involved in patient care.
Percentage of patients started on incident home dialysis and yearly change in percentage initiating home dialysis.
A total of 817 177 adults initiated home dialysis during the study period, of whom 750 314 were included in the study cohort. The cohort included 41.4% women; 26.2% of the patients were Black, 17.4% were Hispanic, and 49.1% were White. Approximately half (49.6%) of the patients were aged at least 65 years. A total of 31.2% received care from health care professionals assigned to ETC participation, and 33.6% had Medicare fee-for-service coverage. Overall, home dialysis use increased from 10.0% in January 2016 to 17.4% in June 2022. Home dialysis use increased more in ETC markets than in non-ETC markets after January 2021 (by 1.07%; 95% CI, 0.16%-1.97%). The rate of increase in home dialysis use in the entire cohort nearly doubled after January 2021 to 1.66% per year (95% CI, 1.14%-2.19%) compared with before 2021, when the rate was 0.86% per year (95% CI, 0.75%-0.97%), but the difference in rate of increase in home dialysis use was not significant between ETC and non-ETC markets.
This study noted that, although the overall rate of dialysis use at home was greater after ETC implementation, the increase occurred more among patients in ETC markets than among those in non-ETC markets. These findings suggest that federal policy and financial incentives affected care for the entire incident dialysis population in the US.
医疗保险和医疗补助服务中心设计了一项强制性支付模式,以激励家庭透析的使用:终末期肾病治疗选择(ETC)。门诊透析机构和提供肾病服务的医疗保健专业人员在医院转诊区域层面被随机分配参与 ETC。
评估 ETC 与实施后前 18 个月内新开始透析人群中家庭透析使用之间的关联。
设计、设置和参与者:使用广义估计方程,对美国终末期肾病质量报告系统数据库进行了具有对照、中断时间序列分析的队列研究。所有在 2016 年 1 月 1 日至 2022 年 6 月 30 日期间在美国开始家庭透析且没有先前肾移植的成年人都包括在分析中。
在 2021 年 1 月 1 日 ETC 开始之前与之后,以及设施和参与患者护理的医疗保健专业人员随机分配参与 ETC。
开始新出现家庭透析的患者百分比和每年开始家庭透析的百分比变化。
在研究期间,共有 817177 名成年人开始家庭透析,其中 750314 名成年人纳入研究队列。该队列包括 41.4%的女性;26.2%的患者为黑人,17.4%为西班牙裔,49.1%为白人。大约一半(49.6%)的患者年龄至少为 65 岁。共有 31.2%的患者接受了分配参与 ETC 的医疗保健专业人员的护理,33.6%的患者有医疗保险按服务收费覆盖。总体而言,家庭透析的使用率从 2016 年 1 月的 10.0%增加到 2022 年 6 月的 17.4%。在 2021 年 1 月之后,ETC 市场的家庭透析使用率增长高于非 ETC 市场(增长 1.07%;95%CI,0.16%-1.97%)。与 2021 年之前相比,整个队列中家庭透析使用率的增长率在 2021 年之后几乎翻了一番,达到每年 1.66%(95%CI,1.14%-2.19%),而 2021 年之前的增长率为每年 0.86%(95%CI,0.75%-0.97%),但 ETC 和非 ETC 市场之间家庭透析使用率增长率的差异无统计学意义。
本研究指出,尽管 ETC 实施后家庭透析的总体使用率更高,但在 ETC 市场中的患者中增长幅度更大。这些发现表明,联邦政策和财政激励措施影响了美国整个新开始透析人群的护理。